Xarelto® Tailored treatment and prevention for your Eligible Cardiovascular Patients^[1]

Based on results from the EINSTEIN Junior trial in children aged 0-17, you can offer paediatric patients an oral anticoagulation to treat VTE and prevent VTE recurrence

^{[1]*,§,††}

Footnotes

^{* Not recommended in patients with CrCl <15 ml/min and in patients with renal impairment when concomitantly receiving medicinal products that increase rivaroxaban plasma concentration.[1]
Not recommended in children 1 year or older with moderate or severe renal impairment (glomerular filtration rate < 50 mL/min/1.73 m[3]),as no clinical data is available.
Not recommended in children younger than 1 year with serum creatinine results above 97.5th percentile, as no clinical data are available.
§ After at least 5 days of parenteral anticoagulation treatment.
†† For all children, except those aged less than 2 years with catheter-related thrombosis: Therapy should be continued for at least 3 months. Treatment can be extended up to 12 months when clinically necessary. There is no data available in children to support a dose reduction after 6 months treatment. The benefit-risk of continued therapy after 3 months should be assessed on an individual basis taking into account the risk for recurrent thrombosis versus the potential bleeding risk. For Children aged less than 2 years with catheter-related thrombosis: Therapy should be continued for at least 1 month. Treatment can be extended up to 3 months when clinically necessary. The benefit-risk of continued therapy after 1 month should be assessed on an individual basis taking into account the risk for recurrent thrombosis versus the potential bleeding risk.
Volume and frequency of administration of Xarelto is dependent on a child’s weight and will need to be adjusted if the child receives Xarelto for a long period of time.}

^{VTE, venous thromboembolism; ARR, absolute risk reduction; BID, twice daily; CI, confidence interval; CrCl, creatinine clearance; LMWH, low-molecular-weight heparin; OD, once daily; R, randomisation; UFH, unfractionated heparin; VKA, vitamin K antagonist; SoC, standard of care.}